Aptima® Chlamydia trachomatis Assay

Protect and improve the reproductive and sexual health of patients through accurate and early detection of Chlamydia trachomatis (CT).

Assay box in lab background

    Overview

    Documents

    Training

    Protecting Reproductive & Sexual Health

    The single target Aptima Chlamydia trachomatis assay provides excellent diagnostic performance across a broad range of specimen types, from both patient and clinician collected samples. This assay adds additional testing flexibility by using an alternative target region to the Aptima Combo 2® assay (for CT/NG), providing more confidence in diagnosis.1,2

    Clarity & Confidence in Every Diagnosis

    The Health Canada approved assay delivers reliable results from multiple specimen types, including self and clinician-collected vaginal swabs, a preferred specimen for CT testing.1

    Confidence in Diagnosis

    The alternate target Aptima CT assay can be used for reflex testing on reactive Aptima Combo 2 samples when additional analysis is required.3

    High Sensitivity & Specificity

    A molecular NAAT (Nucleic Acid Amplification Test) that targets rRNA to ensure excellent assay sensitivity with proven assay performance. Provides an upfront biological advantage compared with assays that detect DNA, as there is up to 1,000-fold more rRNA than DNA per cell.4

    Improve Workflow & Assay Consolidation

    Benefit from efficient workflow, reduced hands-on time and sample volume scalability, by running assays on the fully automated Panther® System.5

    Female lab technician observing Panther systems in lab setting

    Simplify & Scale the Future of Diagnostics

    The Aptima CT Assay is part of the Panther® Scalable Solutions, a portfolio combining a broad, high-performing assay menu with high-throughput automation. Designed to flexibly scale to meet your needs, from a single patient result to population level screening.

    Proven Performance

    Alternate target testing for confidence in Chlamydia trachomatis results.1

    16s rRNA target

    Chlamydia trachomatis (CT)

    Sensitive and specific

    performance across a wide range of sample types

    Symptomatic and asymptomatic

    testing possible

    Aligned with Canadian STI Guidelines

    "For medico-legal purposes, confirmation of positive results can be done with a NAAT using a different set of primers or by DNA sequencing techniques."6

    Gloved hand holding vial rack in a lab setting

    One Sample, Multiple STI Results

    Clinically relevant sample type options make the Aptima CT Assay easy to order as a standalone or in combination with other assays from the automated Hologic STI Solution. Browse relevant collection devices below.

    Man and woman holding hands at outdoors

    Protect Fertility With Accurate Testing

    Chlamydia (CT) can have serious long-term consequences, including pelvic inflammatory disease (PID), ectopic pregnancy and infertility.7 Accurate testing and treatment are critical to protecting sexual and reproductive health.

    Evidence. Insight. Collaboration.

    Our education portal improves patient care through excellence in education, communication of clinical and scientific evidence, and partnerships with the healthcare community.

    Insights

    Healthcare provider looking at scan images on monitor display

    FDA and Health Canada Market Authorization for Genius™ Digital Diagnostics System

    infographic image showing cervical screening view of women

    Discover the Future of Cervical Cancer Screening

    PCR tests in a rack held by a hand wearing gloves

    The Molecular Diagnostics Revolution and its Impact on Personalized Care

      1. Aptima Chlamydia trachomatis Assay [Package Insert] 502184EN Rev. 010. Hologic Inc., 2022
      2. Aptima Combo 2 Assay. [package insert]. AW-20536-001 Rev.004.. Hologic, Inc., 2024
      3. AW-26055-001 Rev. 001  Panther / Panther Fusion Operators Manual 
      4. Chernesky M, Jang D, Luinstra K, et al. High analytical sensitivity and low rates of inhibition may contribute to detection of Chlamydia trachomatis in significantly more women by the APTIMA Combo 2 assay. J Clin Microbiol. 2006;44(2):400- 405.
      5. Ratnam S, Jang D, Gilchrist J et.al.  Workflow and Maintenance Characteristics of Five Automated Laboratory Instruments for the Diagnosis of Sexually Transmitted Infections.  J. Clin. Microbiol. 2014;52(7):2299-2304
      6. Canadian Guidelines on Sexually Tranmitted Infections. Available from https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/chlamydia-lgv.html#a1.3 Accessed September 2024.
      7. Workowski KA, Bachman LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines 2021. MMWR Recomm Rep 2021;70

      Safety Data Sheets

      Package Inserts